Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: kdd999 who wrote (38513)	1/7/2017 8:28:18 PM
From: idahoranch1	4 Recommendations Recommended By btlbail1 immuapproval patlawche11 watchmymovement Respond to of 63291

I've never liked that Goldman Sach's was involved in our bond issue, and then on top of that, they never picked up coverage on the company. So, in effect, they represented the bonds as a good deal for the bond buyers, but not so much the stock of the company. Under current management, the only game being played is the finance game, and the financiers are doing quite well. Another reason this way of doing business has to end.

To: kdd999 who wrote (38513)	1/8/2017 6:46:26 PM
From: EMU2	2 Recommendations Recommended By drtom1234 idahoranch1 Respond to of 63291

I worked for a company that almost got "I-CON"ed. This was in the mid 90's, his 2nd or 3rd attempt at a takeover. He was but a speck of excrement at the time. Even then the company could see what his shtick was. The BOD sought out a friendly takeover, which saved people's jobs and the assets. I bought as many shares in the company that I could early(inside info ;) ) when the stock price increased as he was buying the undervalued stock to facilitate his takeover attempt.. VB is a company with a vision on how to make as much money as possible on the increase in IMMU's stock price. Carl Icahn, in his early days, made money by buying companies and liquidating them. I see no comparison at all between an Individual rapist of companies and a life sciences investment firm. .